ライフサイエンスコーパス: alum

1 us toxoid adsorbed to aluminum hydroxide (TT/Alum).

2 together with FVIII adsorbed in an adjuvant (alum).

3 juvant-based model in wild-type mice (WT-OVA/alum).

4 us type 5 host range mutant empty vector and alum.

5 ombined with CpG 1018 alone or CpG 1018 with alum.

6 ent FLSC proteins or with monomeric gp120 in alum.

7 the Hepatitis B virus vaccine formulated in alum.

8 -desacyl-4'-monophosphoryl lipid A (MPL) and alum.

9 enocytes of mice immunized with CpG 1018 and alum.

10 ion with an intraperitoneal injection of OVA/alum.

11 monovalent or bivalent vaccines with CpG and alum.

12 or by subcutaneous injection with or without alum.

13 ophenol-conjugated chicken gamma-globulin in alum.

14 at were stronger than those induced by Ag in alum.

15 litatively stronger response than GLA, SE or alum.

16 on with ovalbumin (OVA) along with papain or alum.

17 D4 T-cell priming by i.m. injected antigen + alum.

18 ining lymph node in mice immunized i.p. with alum.

19 Host DNA rapidly coats injected alum.

20 grass pollen allergen Phl p 5 together with alum.

21 immunization with ovalbumin (OVA) mixed with alum.

22 were immunized with PM alone or adsorbed to alum.

23 exclusively Th2 humoral response elicited by alum.

24 trols in the chronic OVA model without added alum.

25 onophosphoryl lipid A, a TLR-4 agonist, with alum.

26 pared to vaccinations with soluble VMP001 or alum.

27 p3), is essential for the adjuvant effect of alum.

28 group was immunized with gD2t protein in MPL-alum.

29 owing immunization with Ags in CFA or IFA or alum.

30 yl (NP)-conjugated chicken gamma globulin in alum.

31 ing that both of these cell types can detect alum.

32 oosted twice i.m. with SIV gp120 proteins in alum.

33 affected during treatment with MnO(4)(-) and alum.

34 uvanted in GLA-SE but not when formulated in Alum.

35 ized with ovalbumin (OVA) in the presence of alum.

36 lated PE, except when it was formulated with alum.

37 nge of Spi2A knockout mice with ovalbumin in alum.

38 ree intraperitoneal (i.p.) injections of OVA/alum.

39 n response to inflammatory thioglycollate or alum.

40 erformed in the presence of either GLA-SE or alum.

41 s adjuvanted by monophosphoryl lipid A (MPL)-alum.

42 th an envelope protein (gp120) adjuvanted in alum.

43 somewhat reduces responses to some Ags with alum.

44 ody responses were in the 30 microg RSV-PreF/alum, 60 microg RSV-PreF/alum, and 60 microg RSV-PreF/no

45 to allow adsorption onto aluminum hydroxide (alum), a formulation commonly used in vaccines for antig

46 properties, which is highly comparable with alum, a commonly used adjuvant.

47 nts after parenteral administration to mice: alum, a derivative of the heat-labile toxin (LT), and th

48 nus toxoid vaccine adjuvanted with potassium alum, a human hepatitis B vaccine adjuvanted with alumin

49 Alum activates the intracellular stress sensors inflamma

50 NA to promote migration of inflammatory DCs, alum acts as an adjuvant by introducing host DNA into th

51 spite its widespread use, the means by which alum acts as an adjuvant remains poorly understood.

52 ared with approved or experimental adjuvants alum, AddaVax, and poly(I.C).

53 arly rules out a role for depot formation in alum adjuvant activity.

54 Controls received empty Ad5hr vector and alum adjuvant only.

55 sponse but the combination of lentiVLPs with Alum adjuvant resulted in a more potent response.

56 responses were superior to those induced by alum adjuvant, and they resulted in enhanced protection

57 ing inactivated yellow fever antigen with an alum adjuvant, induced neutralizing antibodies in a high

58 microg of RSV-PreF antigen, with or without alum adjuvant, or control, and followed for one year for

59 rates IFN-beta and neuroantigen (NAg) in the Alum adjuvant.

60 nses to the split vaccine and the effects of alum adjuvant.

61 peptides, conjugated to KLH, delivered with alum adjuvant.

62 es of nontargeted NP-protein conjugates with alum adjuvant.

63 olyvalent, inactivated HRVs plus alhydrogel (alum) adjuvant.

64 cultures and adsorbed to aluminum hydroxide (alum) adjuvant.

65 idal activity (SBA) against MenC compared to alum adjuvanted vaccine, especially with a low dose of a

66 DNA lacking IP-10 and boosted with MPLA-plus-alum-adjuvanted Env protein (DP(ALFA)) The D(IP-10) P(AL

67 mulsion were superior to unadjuvanted or MPL-alum-adjuvanted formulations at eliciting a robust cell-

68 Alum-adjuvanted hepatitis B vaccine elicited vital signs

69 nd infants immunized with the same MF59- and alum-adjuvanted HIV envelope vaccines.

70 After alum-adjuvanted immunization, antigen-specific bone marr

71 ells and optimal humoral responses following alum-adjuvanted immunization.

72 induced by adenovirus vector immunization or alum-adjuvanted protein immunization even if CD4(+)T cel

73 induced by CLDC-adjuvanted vaccine than with alum-adjuvanted vaccine.

74 Although alum-adjuvanted vaccines induced modest costimulatory mo

75 st responses compared to those achieved with alum-adjuvanted vaccines.

76 r understanding of the mechanisms underlying alum adjuvanticity could help to improve AIT vaccine for

77 dentify DC-derived IL-2 as a key mediator of alum adjuvanticity in vivo and the Src-Syk pathway as a

78 In this article, we show that alum adjuvanticity requires IL-2 specifically released b

79 Alum adjuvants have been in continuous clinical use for

80 rated into stable emulsion (SE) (GLA-SE) and alum adjuvants in the cotton rat model.

81 tramuscularly or intravaginally with CpG and alum adjuvants, (i) boosted the highest neutralizing ant

82 otection was observed with both Freund's and alum adjuvants, given subcutaneously and intramuscularly

83 by the formulation of SARS-CoV vaccines with alum adjuvants.

84 ulated with monophosphoryl lipid A (MPL) and alum adjuvants.

85 Aluminum salt (alum) adjuvants have been used for many years as adjuvan

86 i or subcutaneously with aluminum hydroxide (Alum)-adsorbed rBet v 1.

87 asma cell responses compared to conventional alum-adsorbed immunogens.

88 BALB/c mice were sensitized with alum-adsorbed ovalbumin (OVA) and then challenged with a

89 Only subcutaneous immunization with Alum-adsorbed rBet v 1 and epicutaneous administration o

90 colonization compared with immunization with alum alone.

91 hea and death compared to mice immunzed with alum alone.

92 adjuvant based on a TLR7 agonist adsorbed to alum (Alum-TLR7), which is highly efficacious at enhanci

93 imian immunodeficiency virus (SIV) and gp120 alum (ALVAC-SIV + gp120) equivalent vaccine, but not an

94 Vaccination with IFN-beta + NAg in Alum ameliorated NAg-specific sensitization and inhibite

95 , a metal ionophore; and aluminum hydroxide (alum), an immunological adjuvant.

96 Experiments indicated alum, an inexpensive coagulant, was able to remove resid

97 of 20 mug of glycoprotein D from HSV-2 with alum and 3-O-deacylated monophosphoryl lipid A as an adj

98 coinjection of these DNase preparations with alum and Ag reduced the host's immune response to the va

99 We find that alum and an aqueous nanosuspension of GLA synergize to e

100 th wtMVA, MVA-OVA, or PBS, sensitized to OVA/alum and challenged with a diet containing chicken egg w

101 oid (TT) conjugate formulated with adjuvants alum and CpG oligodeoxynucleotide (ODN) generated heroin

102 re, we further investigated the mechanism of alum and DNA's adjuvant function.

103 When used with pure, defined proteins, both alum and emulsion adjuvants are effective at inducing pr

104 adoxically exhibited limited AAI in both OVA-alum and HDM models.

105 Standard ovalbumin (OVA)-alum and house dust mite (HDM) bone marrow-derived DC (B

106 rovide insights into mechanisms of action of alum and introduce a readily translatable approach to si

107 ith a soluble truncated gD protein (gD2t) in alum and monophosphoryl lipid A (MPL) elicited high neut

108 icle (VLP) vaccine candidate adjuvanted with alum and monophosphoryl lipid A (MPL), blockade Ab titer

109 oxoid A and toxoid B vaccine adjuvanted with alum and oral challenge with C. difficile VPI 10463, C57

110 suppression assays were performed to assess alum and PM effects in human dendritic cells (DCs).

111 hoserine (pSer) residues enhances binding to alum and prolongs immunogen bioavailability.

112 ontrast, immunization with NP delivered with alum and the detoxified LPS adjuvant, monophosphoryl lip

113 uvants in approved human vaccines, including alum and the oil-in-water-based emulsions MF59 (Novartis

114 mmunized with the combination of gC2/gD2-CpG/alum and the UL19/UL47 adenovirus vectors.

115 the molecular pathways used by DCs to sense alum and, in turn, activate T and B cells.

116 Again, alum and/or CpG adjuvants did not have an effect on the

117 We demonstrate that alum and/or CpG adjuvants induced similar uptake of anti

118 oth the humoral (>32 times of IgG1 levels vs alum) and the cell-mediated immune responses against the

119 Aluminum salts (alum) and the oil-in-water emulsion MF59 are safe and ef

120 profiled different TLR-independent (MF59 and alum) and TLR-dependent (CpG, resiquimod, and Pam3CSK4)

121 milieus: OVA protein in CFA, aluminum salts (Alum), and Schistosoma mansoni eggs (Sm Egg).

122 30 microg RSV-PreF/alum, 60 microg RSV-PreF/alum, and 60 microg RSV-PreF/nonadjuvant groups.

123 ein immunization with ALVAC-SIV and gp120 in alum, and we challenged them with SIV(mac251) at either

124 ere cultured in autologous plasma; levels of alum- and TLR agonist-induced cytokines and costimulator

125 d vaccinia Ankara (a poxvirus); protein with alum; and protein in the squalene oil-in-water adjuvant

126 The adjuvant alum, approved for use in humans, was as protective as F

127 HO-derived S-2P formulated with CpG 1018 and alum as a candidate vaccine to prevent COVID-19 disease.

128 d; (ii) immunized with gC2/gD2, with CpG and alum as adjuvants; (iii) immunized with the UL19/UL47 ad

129 s were more frequent in the formulation with alum as compared to GLA-SE, whereas local AEs were more

130 The use of GAD-alum as compared with placebo did not affect the insulin

131 fore ultrafiltration, was compared with only alum as pretreatment.

132 was apparent for immunization with VLP-NP or alum as the adjuvant.

133 Many vaccines include aluminum salts (alum) as adjuvants despite little knowledge of alum's fu

134 extensive usage of insoluble aluminum salts (alum) as vaccine adjuvants, the molecular mechanisms und

135 We demonstrate that alum, as well as other sterile particulates, such as uri

136 e was dependent on mucosal sensitization, as alum/Aspergillus-sensitized mice that were rechallenged

137 IMQs were more potent and effective than alum at inducing TNF and IL-1beta from monocytes.

138 lone or the mineral salt aluminum hydroxide (alum) at the muscle injection site over multiple timepoi

139 During jar tests on alum-based drinking water treatment, dissolved Al determ

140 IFN-beta/Alum-based vaccination exhibited hallmarks of infectious

141 lO (1 mg/l as active Cl) in combination with alum, before ultrafiltration, was compared with only alu

142 , with both given as a vector-prime/gp120 in alum boost strategy.

143 minimal gene upregulation induced by SE and alum, both GLA and GLA-SE triggered MyD88- and TRIF-depe

144 Therefore, alum by itself poorly induces Mo-DCs to migrate to drain

145 hypothesized that alum-formulated GAD65 (GAD-alum) can preserve beta-cell function in patients with r

146 Mechanistically, pSer-immunogen:alum complexes form nanoparticles that traffic to lymph

147 on were seen between vaccinated and Ad-empty/alum controls, suggesting responses were due to the Ad-v

148 e candidates alone or adjuvanted with either alum, CpG, or Advax, a new delta inulin-based polysaccha

149 eur's canarypox vector (ALVAC)-HIV and gp120 alum decreased the risk of HIV acquisition in the RV144

150 Alum decreases PD-L1 expression and IL-10 production ind

151 ld-type and Nlrp3(-/-) mice in either acute (alum-dependent) or chronic (alum-independent) OVA models

152 removal of the injection site and associated alum depot, as early as 2 h after administration, had no

153 nes, vaccination with TGF-beta + MOG35-55 in Alum did not increase Treg percentages in vivo.

154 Treatment with GAD-alum did not significantly reduce the loss of stimulated

155 carrier, or choice of adjuvant (Adjuplex or Alum) did not significantly impact elicited FP-directed

156 In the absence of alum, DIV vaccine performed poorly in young animals chal

157 The pSer-modified immunogens formulated in alum elicited greatly increased germinal center, antibod

158 several 'delivery system' adjuvants such as alum, emulsions, liposomes, and polymeric particles.

159 wed that addition of small amounts of LPS to alum enhanced Mo-DC migration.

160 han conventional DCs, the addition of LPS to alum enhanced the overall immunogenicity of Ags presente

161 igen and/or inflammation are responsible for alum enhancement of antigen presentation and subsequent

162 the AipA, Asp14, and OmpA binding domains in alum followed by challenge with A. phagocytophilum The b

163 ts: four doses of GAD-alum, two doses of GAD-alum followed by two doses of placebo, or four doses of

164 re sensitized with intraperitoneal ovalbumin-alum, followed by intranasal challenge with ovalbumin al

165 The optimal dosages of MnO(4)(-) and alum for decoloration of a 17 wt% raw sugar solution (70

166 red all three components, IFN-beta, NAg, and Alum, for inhibition of experimental autoimmune encephal

167 We hypothesized that alum-formulated GAD65 (GAD-alum) can preserve beta-cell

168 Whereas unadjuvanted or alum-formulated vaccines were associated with significan

169 The GMZ2/alum formulation showed good safety, tolerability, and i

170 a modest and selected role for NLRP3 in the alum-free OVA model.

171 mations in immunogenic formulations based on alum, Freund's adjuvant, or two different types of lipos

172 Alum greatly enhances priming of endogenous CD4 and CD8

173 ter a 1:16 dilution of sera from mice in the alum group.

174 ntially supported CD25 upregulation (CFA and Alum > Sm Egg).

175 However, alum hardly induces T helper 1 (Th1) immune responses th

176 ant, which enhances the immune functions and alum has been widely used in human immunization.

177 V(M766&CG7V) gD-gp120 proteins formulated in alum hydroxide (ALVAC/Env) or DNA encoding SIVenv/SIVGag

178 In an OVA/Alum i.p.-sensitization mouse model, Amb-APE was intrana

179 orrelated with a complete protection from TT/Alum/IL-36beta-induced mortality.

180 Alum impairs PM-induced functional FOXP3(+) Treg cells a

181 We uncover novel mechanisms by which alum impairs the tolerogenic properties induced by PM, w

182 f its ability to cleave DNA, suggesting that alum improves CD4 responses to Ag via a pathway other th

183 t influenza virus split vaccine with MF59 or alum in CD4 knockout (CD4KO) and wild-type (WT) mice.

184 allergic asthma was developed with ovalbumin-alum in female Cd39 wild type (Cd39(+/+) ) and deficient

185 ne adjuvants, namely CAF01, IC31, GLA-SE and Alum in mice.

186 ht to investigate the potential influence of alum in the tolerogenic properties imprinted by PM at th

187 found that polymeric nanoparticles surpassed alum in their ability to enhance Ag-specific CD8 and Th1

188 Alum increased antibody titers; MF59(R) induced strong a

189 in either acute (alum-dependent) or chronic (alum-independent) OVA models.

190 ith cholera toxin provided 56% efficacy; and alum induced a Th2-type response that protected 62 to 68

191 The novel finding that alum induced HSP70 suggests that stress is involved in t

192 The combination of IL-36beta and TT/Alum induced the rapid production of TNF-alpha and IFN-g

193 IL-33 did not compromise alum-induced adaptive cellular immunity after i.m. vacci

194 with Ag-SP before or after initiation of OVA/alum-induced allergic airway inflammation or peanut-indu

195 in a murine model of Th2-mediated ovalbumin/alum-induced allergic airway inflammation.

196 mice showed markedly reduced severity in OVA/alum-induced allergic airway inflammation.

197 We compared the severity of OVA/alum-induced allergic lung inflammation in WT BALB/c mic

198 cells was both necessary and sufficient for alum-induced HSC, multipotent progenitor, and granulocyt

199 essary, but indirect, role in the support of alum-induced neutrophilias by expanding both pluripotent

200 cell recruitment and IL-1beta generation in alum-induced peritonitis, which is a typical IL-1 signal

201 and peritoneal IL-1beta production following Alum-induced peritonitis.

202 Vaccine efficacy was associated with alum-induced, but not with MF59-induced, envelope (Env)-

203 Alum induces eosinophil accumulation partly through the

204 bcutaneous immunization of mice with PM plus alum inhibits in vivo induction of Treg cells promoted b

205 Alum inhibits mTOR activation and alters metabolic repro

206 ation of Ag adsorbed to alum, we showed that alum-injected muscles contained large numbers of convent

207 In alum-injected muscles, Mo-DCs were as numerous as conven

208 Alum is a neonatal adjuvant but might confer a T(H)2 bia

209 Recently, it was shown that injected alum is rapidly coated with host chromatin within mice.

210 Alum is the only licensed adjuvant by Food and Drug Admi

211 Aluminum hydroxide (alum) is the most commonly used vaccine adjuvant, yet it

212 CFA and Alum led to robust Treg accumulation, with >50% of all s

213 h a soluble peptide, Leu-Leu-OMe, mimics the alum-like form of necrotic cell death in terms of cathep

214 adjuvant effects, Leu-Leu-OMe replicated an alum-like immune response in vivo, characterized by dend

215 a variety of adjuvant formulations including alum, liposomes, and oil-in-water emulsions to determine

216 tigation were to examine the hypothesis that alum-mediated adjuvanticity is a function of stress and

217 whereas cathepsins B and S were required for alum-mediated necrosis.

218 , but did not affect T-independent type 1 or alum-mediated T-dependent humoral responses or TLR-indep

219 -head comparison of five different adjuvants Alum, MF59(R), GLA-SE, IC31(R) and CAF01 in mice and com

220 etween adults and infants immunized with the alum/MNrgp120 vaccine (gp120 median fluorescence intensi

221 s of OVA-specific IgE compared to the WT-OVA/alum model.

222 Proinsulin/alum monotherapy failed to correct hyperglycemia, while

223 Proinsulin/alum monotherapy induced interleukin (IL)-4- and IL-10-s

224 These two groups were boosted with MPL and alum (MPL-alum) together with either formalin-inactivate

225 ith RG1-VLP adjuvanted with human-applicable alum-MPL (aluminum hydroxide plus 3-O-desacyl-4'-monopho

226 combining ivag HPV-gBsec/gDsec and i.m. gD2t-alum-MPL improved survival and reduced genital lesions a

227 ness of different vaccines, we tested gD2 in alum/MPL, gD2 in Freund's adjuvant, and dl5-29 (a replic

228 ived 4 doses of ALVAC-HIV-1/AIDSVAX B/B with alum (n=9) or placebo (n=13) between 0 and 12 weeks of a

229 =48), VaxGen rgp120 with aluminum hydroxide (alum; n=49), or placebo (n=19) between 0 and 20 weeks of

230 ent in the muscle induced by MF59 but not by alum or incomplete Freund's adjuvant.

231 d by ALVAC-SIV/gp120 vaccination, given with alum or MF59 adjuvant, to capture infectious SIVmac251 a

232 d whether the addition of a gp120 protein in alum or MVA-expressed secreted gp140 (MVAgp140) could im

233 In contrast, the adjuvant effects of Alum or parent MDP show a strong Th2-bias (dominance of

234 alpha11-88x8 or alpha11-88x5 adjuvanted with alum or the licensed HPV vaccines and challenged intrava

235 At such low doses, the conventional adjuvant alum or the molecular adjuvants monophosphoryl lipid A (

236 CD40L on T cells in the animals treated with alum or the stress agents mediate the interactions betwe

237 fluenza vaccine administered with MF59, with alum, or delivered unadjuvanted.

238 ularly with monophosphoryl lipid A (MPL) and alum, or gC2 and gD2 were produced in glycoengineered Pi

239 Direct uptake of antigen-decorated alum particles by B cells upregulated antigen processing

240 V(M766&CG7V) gD-gp120 proteins formulated in alum phosphate (DNA&Env).

241 poly)glycerolphosphate and tetanus toxoid in alum plus CpG-oligodeoxynucleotides produced high second

242 presensitized with intraperitoneal ovalbumin/alum plus oral ovalbumin.

243 cells (OTI) and the response to subcutaneous alum-precipitated ovalbumin was followed in the draining

244 factors during a T-dependent Ab response to alum-precipitated protein in mouse lymph nodes.

245 dA IgG titers were enhanced by administering alum-precipitated protein, a modest additional protectio

246 Th2 Ags such as alum-precipitated proteins and helminths induce IgG1, wh

247 DC into the ocular mucosa of ovalbumin (OVA)/alum-primed mice.

248 VAC vaccine coupled with the monomeric gp120/alum protein have decreased the risk of HIV and SIV acqu

249 Alum remains the most widely used adjuvant in AIT, but i

250 S. Typhi(F1), as opposed to priming with F1-alum, resulted in a more balanced IgG2a/IgG1 profile, en

251 the ability of DNase preparations to inhibit alum's adjuvant activity.

252 DNA in the coating chromatin contributed to alum's adjuvant activity.

253 um) as adjuvants despite little knowledge of alum's functions.

254 the levels induced by s.c. injection of OVA/alum (SCIT).

255 ic asthma was induced by intraperitoneal OVA/alum sensitization followed by repeated OVA airway chall

256 mally after stimulation with ATP, nigericin, alum, silica, flagellin, or cytoplasmic DNA, indicating

257 The laboratory scale alum sludge-based intermittent aeration constructed wetl

258 ectious tolerance, because IFN-beta + OVA in Alum-specific vaccination inhibited EAE elicited by OVA

259 4] agonist glucopyranosal lipid A [GLA] plus alum, squalene-oil-in-water emulsion, and GLA plus squal

260 of (S)MLMH-TT adjuvanted with CpG ODN 1826 + alum successfully raised anti-METH antibodies in high ti

261 in our laboratories (SMIP.7-10) adsorbed to alum, the five antigens provided close to 100% protectio

262 When formulated with alum, the monomeric cysteine mutants induced a similar i

263 atible with many vaccine adjuvants including alum, the most common adjuvant used in the vaccine marke

264 diated cell death in immunity and found that alum, the most commonly used adjuvant worldwide, trigger

265 Compared with alum, the protective efficacy of the pandemic H1N1 influ

266 While with fresh alum, the removal efficiencies of total suspended solids

267 T follicular helper (TFH) and Th1 cells than alum, the SE alone, or GLA without SE.

268 mall molecule immune potentiator (SMIP) onto alum, thereby enhancing co-delivery with antigen.

269 Ultimately, compared with alum, this system offered superior protection in a mouse

270 Finally, we demonstrate that Alum-TLR7 adjuvant effect requires a functional TLR7.

271 Alum-TLR7 also drives antibody response towards Th1 isot

272 Taken together, our data support the use of Alum-TLR7 as adjuvant for glycoconjugate vaccines.

273 We found that in a mouse model Alum-TLR7 greatly improved potency of a CRM197-MenC vacc

274 Furthermore, we found that Alum-TLR7 increases anti-polysaccharide immune response

275 ugate vaccines in humans, we investigated if Alum-TLR7 is able to improve immunogenicity of this clas

276 nt based on a TLR7 agonist adsorbed to alum (Alum-TLR7), which is highly efficacious at enhancing imm

277 nide as adjuvants to favor a Th1 response or alum to elicit a Th2 response.

278 ly as a bivalent vaccine with Iscomatrix and alum to HSV-1-naive or -seropositive guinea pigs.

279 o groups were boosted with MPL and alum (MPL-alum) together with either formalin-inactivated mock HSV

280 h four different human-compatible adjuvants (alum, Toll-like receptor 4 [TLR-4] agonist glucopyranosa

281 ibody responses to tier 2 HIV-1 strains with alum treatment alone in the absence of Env.

282 of three study treatments: four doses of GAD-alum, two doses of GAD-alum followed by two doses of pla

283 IFN-beta + NAg in Alum vaccination elicited elevated numbers and percentag

284 this study indicates that IFN-beta + NAg in Alum vaccination elicits NAg-specific, suppressive CD25(

285 ting responses were due to the Ad-vector and alum vaccine components.

286 Immunization with recombinant ALVAC/gp120 alum vaccine provided modest protection from human immun

287 Unlike IFN-beta + NAg in Alum vaccines, vaccination with TGF-beta + MOG35-55 in A

288 ve FOXP3(+) Tregs in vitro in the absence of Alum via a mechanism that was neutralized by anti-TGF-be

289 The toxicity of IL-36beta + TT/Alum was abrogated by the administration of a neutralizi

290 ergic inflammatory response to ovalbumin and alum was unimpaired.

291 nation with CpG 1018 and aluminum hydroxide (alum) was found to be the most potent immunogen and indu

292 nderstand more about how the body recognizes alum we characterized the early innate and adaptive resp

293 After i.m. administration of Ag adsorbed to alum, we showed that alum-injected muscles contained lar

294 uantity and quality than aluminum hydroxide (alum), which is currently the most widely used adjuvant

295 nd adjuvanticity, commensurate with those of alum, which may provide an alternative strategy in devel

296 se BZN-phosphonates are highly adsorbed onto alum, which significantly reduced systemic exposure and

297 ctedly, the combination of IL-36beta with TT/Alum, which was well tolerated in AD mice, proved toxic

298 The substitution of alum with the more immunogenic MF59 adjuvant is under co

299 ct of combining a prototypic ABT, proinsulin/alum, with GABA treatment in newly diabetic NOD mice.

300 and equally effective compared to SCIT with alum, without the need for adjuvant.